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Progressive severe lung injury by zinc oxide
nanoparticles; the role of Zn2+ dissolution inside
lysosomes
Wan-Seob Cho1, Rodger Duffin1, Sarah EM Howie2, Chris J Scotton3, William AH Wallace4, William MacNee1,
Mark Bradley5, Ian L Megson6 and Ken Donaldson1*
Abstract
Background: Large production volumes of zinc oxide nanoparticles (ZnONP) might be anticipated to pose risks, of
accidental inhalation in occupational and even in consumer settings. Herein, we further investigated the
pathological changes induced by ZnONP and their possible mechanism of action.
Methods: Two doses of ZnONP (50 and 150 cm2/rat) were intratracheally instilled into the lungs of rats with
assessments made at 24 h, 1 wk, and 4 wks after instillation to evaluate dose- and time-course responses.
Assessments included bronchoalveolar lavage (BAL) fluid analysis, histological analysis, transmission electron
microscopy, and IgE and IgA measurement in the serum and BAL fluid. To evaluate the mechanism, alternative
ZnONP, ZnONP-free bronchoalveolar lavage exudate, and dissolved Zn2+ (92.5 μg/rat) were also instilled to rats.
Acridine orange staining was utilized in macrophages in culture to evaluate the lysosomal membrane
destabilization by NP.
Results: ZnONP induced eosinophilia, proliferation of airway epithelial cells, goblet cell hyperplasia, and pulmonary
fibrosis. Bronchocentric interstitial pulmonary fibrosis at the chronic phase was associated with increased
myofibroblast accumulation and transforming growth factor-b positivity. Serum IgE levels were up-regulated by
ZnONP along with the eosinophilia whilst serum IgA levels were down-regulated by ZnONP. ZnONP are rapidly
dissolved under acidic conditions (pH 4.5) whilst they remained intact around neutrality (pH 7.4). The instillation of
dissolved Zn2+ into rat lungs showed similar pathologies (eg., eosinophilia, bronchocentric interstitial fibrosis) as
were elicited by ZnONP. Lysosomal stability was decreased and cell death resulted following treatment of
macrophages with ZnONP in vitro.
Conclusions: We hypothesise that rapid, pH-dependent dissolution of ZnONP inside of phagosomes is the main
cause of ZnONP-induced diverse progressive severe lung injuries.
Background
Zinc oxide nanoparticles (ZnONP) are utilised in many
commercial products including cosmetics, paints, textiles,
food additives, and personal hygiene products. Because
ZnONP are translucent and highly effective in protection
against ultraviolet A and B radiation, they are important
ingredients of sunscreens and moisturizers [1]. ZnONP is
widely used as an ingredient of paints and coating and
finishing materials in products and buildings because
they provide long-term protection from ultraviolet light
[2]. ZnONP have also been used as a dietary supplement
in human and livestock because Zinc can stimulate
immune systems and act in an anti-inflammatory way
[3,4]. ZnONP has external uses as antibacterial agents in
ointments, lotions, mouthwashes, and surface coatings to
prevent microorganism growth [5].
There are few toxicity reports on ZnONP despite their
widespread use and potential for use in various applica-
tions. Toxicity studies of ZnONP have mainly focused on
dermal toxicity, of relevance due to the inclusion of
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ZnONP within materials that are directly applied to skin.
Penetration of ZnONP through normal skin was limited
to the stratum corneum in porcine [6] and human mod-
els [7]. Exposure of human skin epithelial cells to
ZnONP produced severe cytotoxicity accompanied by
oxidative stress and genotoxicity [8]. Few studies have
been reported concerning the in vivo toxicity of ZnONP
although intratracheal instillation of ZnONP (50 - 70
nm) in Sprague-Dawley rats induced cytotoxicity and
neutrophilic inflammation at 24 h after instillation [9].
Previously, we assessed the pulmonary inflammogenicity
of a large panel of NP, including ZnONP and found that
metal oxide NP elicited diverse patterns of inflammation
with different cellular bases, at both the acute and chronic
phase [10]. In the present study, we extended these experi-
ments to specifically evaluate the mechanisms of eosino-
philic inflammation and pulmonary fibrosis induced by
ZnONP instillation.
Methods
We briefly described materials and methods in the main
text but the detailed methods were described in the
Additional file 1.
Characterization and dispersion of NP
ZnONP (10.7 ± 0.7 nm) were purchased from NanoScale
Corporation (Manhattan, KS, USA) (Table 1). Surface area
of ZnONP was determined with a Micromeritics TriStar
3000 (Bedfordshire, UK) by Escubed Ltd. (Leeds, UK). For
dispersion of ZnONP, 5% of heat-inactivated rat serum
(collected from the healthy female Wistar rat) was added
to saline (Baxter, Deerfield, IL, USA) for final concentra-
tions. The endotoxin levels of ZnONP at 300 cm2/ml were
determined using a Limulus Amebocyte Lysate assay kit
(Cambrex, Walkersville, MD, USA). The hydrodynamic
size and zeta potential of ZnONP in PBS with 5%
rat serum were assessed with a Brookhaven 90 plus
(Holtsville, NY, USA) and Zetasizer-Nano ZS instrument
(Malvern, Malvern Hills, UK), respectively.
Durability of ZnONP
To evaluate the biopersistence of ZnONP in vivo, ZnONP
were incubated with artificial lysosomal fluid (ALF) [11]
and artificial pulmonary interstitial fluid (Gamble’s solu-
tion) [12]. As a control particle, the rutile form of TiO2NP
(30.5 ± 1.8 nm) was purchased from Nanostructure and
Amorphous Materials Inc. (Houston, TX, USA) (Table 1).
ALF (pH 4.5) and Gamble’s solution (pH 7.4) were
prepared as previously described [11,13]. ZnONP and
TiO2NP were incubated with ALF or Gamble’s solution at
5 mg/ml for 24 h at 37°C with gentle shaking. After 24 h,
50 mg of suspensions were centrifuged at 13 000 × g for
30 min and the supernatant discarded. After the final
wash with distilled water (DW), pellets were air dried and
resuspended in 5 ml of DW. NP suspensions were then
weighed and calculated by subtraction of the weight of the
container and the same volume of distilled water. There is
potential for some error in this method due a small frac-
tion of small NP that could remain in suspension after
centrifugation and are lost on washing.
Intratracheal instillation of ZnONP
Female Wistar rats (200 - 250 g) were humanely main-
tained and handled in accordance with the UK Home
Office Animals Scientific Procedures Act. Intratracheal
instillation was performed as previously described method
[10]. ZnONP were instilled at a surface area dose of 50 or
150 cm2/rat, and 5% rat serum in saline was used as the
vehicle control (n = 5 - 7 per group). Large agglomerates
of ZnONP (diameter- 4,380 nm) in saline without rat
serum also instilled at 150 cm2 per rat to evaluate the
effects of agglomeration on eosinophilia. We used surface
area as a dose metric rather than mass because surface
area has been known as a better descriptor of potential of
NP to cause toxicity in vitro and in vivo [14]. To evaluate
the time-course of the consequent inflammation, rats were
sacrificed at 24 h, 1 wk, and 4 wks after instillation. Pre-
paration of bronchoalveolar lavage (BAL) fluid and analy-
sis for LDH and total protein was performed as previously
described method [10].
ELISA for pro-inflammatory mediators
Measurements of cytokines (TNF-a, IL-1b, IL-13, and
TGF-b) and chemokines (MIP-2 and eotaxin) were per-
formed in non-diluted BAL fluid following the manufac-
turer’s instructions [IL-13 ELISA was obtained from
Invitrogen (Camarillo, CA, USA) and other assays were
from R&D Systems (Minneapolis, MN, USA)]. The
detection limits of ELISA kit was as follow: TNF-a- 5
pg/ml; IL-1b- 5 pg/ml; TGF-b- 1.7 - 15.4 pg/ml; MIP-2-
0.5 - 2.7 pg/ml; eotaxin- 3 pg/ml; IL-13- 1.5 pg/ml.
IgE and IgA ELISA in the serum and BAL fluid
To evaluate the serum immunoglobulin E (IgE) levels,
ZnONP were instilled into rats (n = 4) at 150 cm2 per rat
and blood was taken via the tail vein at day 1 and week 1,
2, 3, and 4 after instillation. Serum was then collected
and diluted 1 in 10 with PBS. Total serum IgE and IgA
levels were determined using a rat IgE ELISA set and rat
IgA ELISA set, respectively (all from BD Biosciences,
Oxford, UK).
Histological analysis (H&E, PSR, and PAS staining)
At each time point, histological analysis of lung tissues
and picrosirius red (PSR) staining was performed as pre-
viously describe method [10]. For detection of goblet
cells which contain mucin, periodic acid-Schiff (PAS)
(Sigma-Aldrich) staining was performed according to
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standard methods. The quantitative image analysis of
PAS-positive cells was performed using Image-Pro Plus
(Media Cybernetics, MD, USA). PAS-positive signals in
the airways were separately evaluated according to air-
way diameter; airways smaller than 1 mm were consid-
ered to be small airways or bronchioles and larger than
1 mm were considered to be a large airway or bronchi
[15]. The total area of PAS-positive cells was divided by
the total area of epithelial cells including basement
membrane. The data were expressed as percentage of
PAS-positive area versus total epithelial area.
Immunohistochemistry for eotaxin, TGF-b, and a-SMA
Immunohistochemical staining for eotaxin, transforming
growth factor-beta (TGF-b), and alpha-smooth muscle
actin (a-SMA) was performed on lung sections. The
detailed method for immunohistochemistry was
described in Additional file 1.
Transmission electron microscopy (TEM)
TEM was used to evaluate ultra-structural changes in
the lungs induced by instillation of ZnONP. Lungs of
vehicle control and ZnONP treated rats 4 wks after
instillation were fixed with 1.5% glutaraldehyde in 0.1 M
cacodylate buffer, stained en bloc with uranyl acetate,
and embedded in epoxy resin. Ultra-thin (60 nm) sec-
tions were cut, stained with uranyl acetate and lead
citrate, and examined with a TEM (JEM-1200EX II,
JEOL, Tokyo, Japan).
Instillation of alternative ZnONP
To evaluate whether the eosinophilic inflammation was
induced by specific types of ZnONP, we instilled another
type of ZnONP (designated ZnONPalt) into rats. ZnONPalt
were purchased from Nanostructural and Amorphous
Materials, Inc. (Houston, TX, USA) (Table 1). ZnONPalt
were instilled into female Wistar rats at 310 μg per rat,
which is the same mass of 150 cm2 per rat as the ZnONP
from NanoScale Corporation. Four rats were used for each
treatment group. After 24 h, rats were euthanized and
BAL collection and analysis was performed as described
above.
Instillation of ZnONP-free BAL extract to rats
To evaluate whether inflammatory mediators produced
by ZnONP instillation can produce similar pathologies
Table 1 Characterization of nanoparticles
Designated name ZnONP ZnONPalt NiONP TiO2NP
Supplier NanoScale
Corp.
Nanostructure and
Amorphous Materials Inc.
Nanostructure and
Amorphous Materials Inc.
Nanostructure and
Amorphous Materials Inc.
Diameter (nm) examined by TEM 10.7 ± 0.7 137 ± 9.2 5.3 ± 0.4 30.5 ± 1.8
Surface area (m2/g)a 48.2 50 91.8 27.5
Mass (μg) per 150 cm2 (high dose-
rat)
310 - 163.5 545
Mass (μg) per 50 cm2 (low dose-
rat)
103 - 54.5 182
Mass (μg) per 15 cm2 (high dose-
mouse)
31 - 9.18 -
Zn2+ (μg) equivalent to 50 cm2
(rat study)
82.8 - - -
Endotoxin (EU/ml)b ND ND ND ND
Hydrodynamic
size (nm) in
DW 2855 ± 773 4833 ± 625 1210 ± 471 787 ± 324
PBS 3925 ± 715 5683 ± 510 2236 ± 407 1166 ± 344
PBS (5% rat
serum)
423 ± 24 282 ± 124 93 ± 4 119.1 ± 39.6
PBS (5%
mouse serum)
229 ± 187 - 83 ± 44 -
Zeta potential
(mV) in
PBS (5% rat
serum)
-27.1 ± 1.4 -25.9 ± 0.6 -26.0 ± 5.0 -28.5 ± 5.2
PBS (5%
mouse serum)
-18.9 ± 1.5 - -21.4 ± 0.8 -
Values are mean ± S.D. from four independent experiments.
ND = not detectable.
aDetermined by Escubed Ltd. (Leeds, UK).
bLower detection limit 0.1 EU/ml.
DW, distilled water.
PBS, phosphate buffered saline.
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to that seen with ZnONP treatment, we extracted
ZnONP-free BAL fluid and instilled this in rats. The
detailed method was described in Additional file 1.
Instillation of dissolved Zn2+ to rats
To evaluate the effects of dissolved Zn2+ in the acidic solu-
tion, 1 mg/ml of ZnONP in HCl-acidified saline were dis-
solved at a pH of 4.5. After 1 wk, ZnONP-free supernatant
was collected by three rounds of centrifugation at 13000 ×
g. The supernatant was filtered three times through a 0.22
μm filter (Millipore, Cork, Ireland) to exclude possible
bacterial contamination. The concentration of Zn2+ of
supernatant was measured by inductively coupled plasma-
atomic emission spectrometry (ICP-OES) (Perkin Elmer
Optima 5300 DV ICP-OES). The pH of the dissolved Zn2+
was 6.5, which was less acidic than 0.9% saline (pH 5.5).
Thereafter 92.5 and 277.5 μg of Zn2+ were instilled intra-
tracheally into rats and cytological and histological evalua-
tion was performed at 24 h and 4 wks after instillation.
The small discrepancy between the figure of 92.5 μg that
was used in the experiment and the 82.8 μg that should
have been used, was the result of an error where we ori-
ginally calculated the equivalent Zn2+ dose for ZnONP
based on the zinc metal weight rather than zinc oxide
weight.
Aspiration of ZnONP into mice
To evaluate whether the eosinophilic inflammation was a
species- and strain-specific phenomenon, ZnONP were
aspirated into C57BL/6 and BALB/c mice. ZnONP were
dispersed in 5% heat-inactivated mouse serum (collected
from healthy C57BL/6 mice) to a dose of 150 cm2/ml and
100 μl (15 cm2 ZnONP) were aspirated into the lungs of
mice which were sacrificed 24 h later. As a control,
NiONP (Table 1) known to cause acute neutrophilic
inflammation [10] were aspirated at the same surface area
dose. Four mice per each group were used for cytological
evaluation. Eotaxin (R&D systems) and IL-13 (Invitrogen)
levels were measured in the BAL samples as described
above. TEM was also applied to evaluate the ultra-struc-
tural changes in the lung with the same method described
above.
Acridine orange staining
To evaluate the lysosomal membrane destabilization by
NP, acridine orange staining was applied to THP-1 cells.
Human monocytic cell line THP-1 was obtained from
American Type Culture Collection (ATCC) and cultured
at 37°C with 5% CO2 in RPMI containing 10% FBS, 2 mM
L-glutamine (Life Technologies, Paisley, UK), 100 IU/ml
penicillin, and 100 U/ml streptomycin (Life Technologies).
THP-1 cells (1 × 106 cells/ml) were seeded to a μ-Dish35
mm, high (Thistle Scientific Ltd., Glasgow, UK) and differen-
tiated using 10 ng/ml of phorbol myristate acetate (PMA;
Sigma-Aldrich) for 48 h. After activation, cells were
washed three times with PBS and stained with 5 μg/ml
acridine orange (Sigma-Aldrich) for 15 min. Cells were
then washed three times with PBS and were treated with
ZnONP (10 cm2/ml; 20 μg/ml) for 24 h. As a control,
TiO2NP (10 cm
2/ml; 36 μg/ml) were used. Cells were
examined and photographed in a Leica SP5 confocal
microscope (Leica Microsystems, Buckinghamshire, UK).
Cytotoxicity was also measured using a lactated dehydro-
genase assay kit according to the manufacturer’s manual
(Roche Diagnostics Ltd.).
Statistical analysis
Data are expressed as mean ± S.D. and were analyzed with
GraphPad InStat software (Version 3, GraphPad Software,
Inc., La Jolla, CA). To compare each treatment group,
one-way analysis of variance with Tukey’s post hoc pair-
wise comparisons was applied. Student t-test was applied
for comparison between vehicle control and ZnONP treat-
ment group in C57BL/6 and BALB/c mice or ZnONPalt
treatment group. We considered p < 0.05 to be statistically
significant.
Results
Characterization of ZnONP
ZnONP showed a “hard agglomerates” which is not readily
dispersed without any stresses (mechanical or sonication)
in both PBS and DW (Table 1). However, when ZnONP
were dispersed with serum protein, they showed a “soft
agglomerates” which is readily dispersed without any stres-
ses (mechanical or sonication) because of the protein cor-
ona on the surface of NP. The zeta potential of ZnONP in
PBS was determined as -27.13 ± 1.36 mV. Endotoxin levels
of ZnONP suspensions and rat serum were below the
lower detection limit (0.1 EU/ml) whilst 5% mouse serum
was calculated to contain 0.09 ± 0.02 EU/ml.
Durability of ZnONP
Around 90% of ZnONP mass was dissolved within 24 h by
incubation with artificial lysosomal fluid at pH 4.5, whilst
ZnONP in artificial interstitial fluid (Gamble’s solution,
pH 7.4) showed no dissolution (Figure 1). TiO2NP as a
control showed no dissolution or loss of mass either in
ALF or in Gamble’s solution (data not shown). The pre-
sence of proteins/serum did not influence the durability of
ZnONP (data not shown).
Differential cell counts in the BAL fluid
Instillation of ZnONP produced significant increases in
the total cell number at 1 wk and 4 wks, whilst at 24 h
there was no significant change compared to control
(Figure 2A). The number of polymorphonuclear leuko-
cytes (PMN) was significantly increased at 24 h and
returned to control levels thereafter (Figure 2B). The
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number of eosinophils was significantly increased at all
time points and peaked at 1 wk after instillation (Figure
2C). The number of lymphocytes showed no significant
changes in any treatment group. Representative images
of BAL cells show that some giant cells were found at 4
wks after instillation (Figure 2G).
Total protein and LDH in the BAL fluid
The levels of total protein and LDH in the BAL were
significantly increased at 24 h after instillation and
were comparable to controls thereafter except for total
protein at 1 wk with low-dose ZnONP (Figures 2H
and 2I).
Pro-inflammatory cytokine levels in BAL fluid
The level of IL-1b was significantly increased 24 h and 1
wk after instillation of 150 cm2 ZnONP (Figure 2J).
Eotaxin expression was significantly increased only at
24 h with both doses whilst IL-13 was increased at 24 h
and 1 wk with the 150 cm2 dose only (Figures 2K and
2L). The concentrations of IL-1b, eotaxin, and IL-13 in
the BAL were dose-related. The levels of TGF-b in the
BAL peaked at 24 h and were still significantly increased
at 1 and 4 wks after instillation. However, levels of TNF-
a and MIP-2 showed no significant changes compared
to controls (data not shown).
IgE and IgA levels in the serum and BAL fluid
Serum IgE levels were transiently increased at 24 h and
1 wk following instillation of ZnONP instillation and
were similar to controls thereafter (Figure 3A). However,
IgE levels in the BAL were not significantly increased by
any treatment (data not shown). IgA levels in the serum
were significantly down-regulated 2, 3, and 4 wks after
ZnONP instillation (Figure 3B). IgA levels in the BAL
showed no significant changes compared to vehicle con-
trol (Figure 3C).
Lung histopathology
ZnONP induced diverse pathological lung lesions both
at the acute and chronic phase. The representative
pathological lesions could be classified as eosinophilic
inflammation, airway epithelial cell injury, regenerative
proliferation, goblet cell hyperplasia, and pulmonary
fibrosis with atelectasis (collapse of lung tissue affecting
part or all of a lung).
Eosinophilic inflammation
ZnONP induced severe eosinophilic inflammation in the
lung tissues which was consistent with BAL fluid analysis
(Figures 4C and 4D). Eosinophils were mainly present in
interstitial areas including alveolar septum, peribronchial,
peribronchiolar, and perivascular interstitium at all time
points. Eosinophils in the alveoli were greatly increased at
1 wk, consistent with cytological analysis (Figure 4D).
Lungs treated with ZnONP showed proliferation of type II
cells 24 h and 1 wk after instillation (Figures 5B and 5C).
At 4 wks after instillation, foamy macrophages had infil-
trated into the alveoli and the eosinophilic inflammation
was almost resolved (Figure 4E). Eotaxin, a specific che-
moattractant for eosinophils, was strongly expressed at
24 h after ZnONP instillation (Additional file 2). The cells
that stained most intensely for eotaxin were bronchial/
bronchiolar epithelial cells although inflammatory cells
were also positive for eotaxin to some extent.
Airway epithelial cell injury and goblet cell hyperplasia
One of the most striking pathological effects of exposure
to ZnONP was goblet cell hyperplasia and proliferation
of airway epithelial cells including bronchial and bronch-
iolar epithelium. The normal bronchiolar epithelium is
mainly composed of ciliated epithelial cells, goblet cells,
Figure 1 Durability of ZnONP in artificial lysosomal fluid (ALF, pH 4.5) and artificial interstitial fluid (Gamble’s solution, pH 7.4). ZnONP
were incubated at 37°C for 24 h with gentle shaking. (A) Gross picture taken by digital camera. The photographs were taken before
centrifugation. (B) Percentage of mass compared to initial mass (50 mg). Values are mean ± S.D. n = 3.
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Clara cells, and basal cells. In general, goblet cells are
seen occasionally in PAS-stained section in the larger air-
ways but are sparse in the bronchioles and absent from
the terminal bronchioles where Clara cells predominate.
Following ZnONP instillation, ciliated epithelial cells and
basal cells became more basophilic and proliferation
increased compared to vehicle control (Figure 4). The
proliferation of airway epithelial cells was also confirmed
by Ki-67 immunohistochemistry (Figure 5) showing that
proliferation peaked at 24 h, was still apparent at 1 wk
and had returned to control levels at 4 wks after instilla-
tion. Interestingly, the proliferation of airway epithelial
cells was accompanied by striking hyperplasia of goblet
cells which produce mucus (Figure 6). Goblet cells in the
airway epithelium had undergone florid hyperplasia in
both bronchi and bronchioles at 1 and 4 wks with the
entire radius of the bronchiole being composed of goblet
cells in some sections. At 1 wk, goblet cells could be
Figure 2 Bronchoalveolar lavage (BAL) analysis 24 h, 1 wk, and 4 wks after instillation of ZnONP to rats. (A - G), cytological analysis of
BAL after instillation of ZnONP at 50 and 150 cm2/rat. (A), number of total cells; (B), number of PMN; (C), number of eosinophils. Representative
BAL cell images of vehicle control (D) and ZnONP instillation (150 cm2) at 24 h (E), 1 wk (F), and 4 wks (G). Black arrows indicate alveolar
macrophages; blue arrows indicate PMN; red arrows indicate eosinophils; green arrows indicate giant cells. (H and I), levels of total protein (H)
and LDH (I) in the BAL from rats treated with ZnONP. Levels of LDH in BAL expressed as fold-change compared to vehicle control. (J - M),
expression of inflammatory mediators in the BAL from rats instilled with ZnONP. (J), IL-1b; (K), eotaxin; (L), IL-13; (M), TGF-b. Values are mean ± S.
D. n = 6 for 24 h and 4 wks groups and n = 4 for 1 wk groups. Significance versus vehicle control (VEH): * p < 0.05, ** p < 0.01, # p < 0.001.
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found even in terminal bronchioles, but were not present
in the transitional region between bronchiolar and alveo-
lar tissue (Additional file 3). Whilst the goblet cell hyper-
plasia was transient at 1 wk, a modest excess of goblet
cells were still evident at 4 wks.
Pulmonary fibrosis
Instillation of ZnONP induced interstitial and broncho-
centric patterns of fibrosis, contraction and atelectasis of
parenchymal lung tissue which was obvious as both
gross lesions and in histological sections (Figure 4). The
areas of fibrosis were evident especially at 1 and 4 wks
after instillation, using picrosirius red (PSR) staining,
(Figures 7C and 7D). The fibrotic and atelectatic lesions
ran in bands through the parenchyma and where they
met the pleura, caused puckering of the visceral pleural
surface. Alpha-SMA, a myofibroblast marker, and trans-
forming growth factor-b (TGF-b) were strongly
expressed in these bands of fibrosis/atelectasis 1 and 4
wks after instillation (Figure 8). TEM examination
showed large bundles of collagen, eosinophils, and neu-
trophils located in the interstitium and foamy vacuolated
macrophages in the alveolar spaces in the lungs of
ZnONP treated rats 4 wks after instillation (Figure 9).
In addition to pulmonary fibrosis, the smooth muscle
Figure 3 IgE and IgA levels after instillation of ZnONP at 150
cm2/rat. (A) IgE levels in serum; (B) IgA levels in serum; (C) IgA levels in
BAL fluid. Values are mean ± S.D. n = 4 - 8 for each treatment group.
Significance versus vehicle control: * p < 0.05, ** p < 0.01, # p < 0.001.
Figure 4 Representative gross lesion and histology of lungs
after instillation of ZnONP at 150 cm2/rat. (A), lungs were
contracted and collapsed by ZnONP treatment and this caused
puckering of the lung surface. (B - E), each figure is composed of a
low power view (left, 25×), high power view of bronchiolar
epithelium (middle, 400×), and alveoli (right, 400×). (B) vehicle
control at 24 h; (C) ZnONP at 24 h; (D) ZnONP at 1 wk; (E) ZnONP
at 4 wks. Red arrows indicate eosinophils and arrowheads indicate
foamy macrophages. Black arrows indicate goblet cells.
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layer in the bronchi and bronchioles was thickened 1
and 4 wks after ZnONP instillation (Figure 4).
Instillation of agglomerated ZnONP
Large poorly-dispersed agglomerates of ZnONP (dia-
meter- 4,380 nm) produced around 91,000 eosinophils
(1.3%) in the BAL whilst well-dispersed ZnONP (dia-
meter- 242.9 nm) produced 595,000 eosinophils (36.7%)
in the BAL (Additional file 4).
Study with alternative ZnONP
To evaluate whether eosinophilic inflammation was a
generic property of ZnONP, we instilled ZnONP
obtained from an alternative commercial source that
were slightly larger in size distribution (90 - 210 nm in
size) into female Wistar rats. This ZnONP sample
(designated ZnONPalt) significantly increased the num-
ber of PMN and eosinophils in the BAL following instil-
lation (Figures 10B and 10C). In addition, ZnONPalt
induced similar levels of LDH and total protein com-
pared to ZnONP at the same mass dose (Figures 10E
and 10F).
Effects of NP-free BAL fluid on inflammation in rat lungs
NP-free BAL fluid collected 24 h after instillation of
ZnONP into rats was instilled into naïve rat lungs.
There was no inflammation at 1 and 4 wks after instilla-
tion of NP-free BAL fluid from ZnONP-exposed lungs
(data not shown).
Inflammatory pattern of dissolved Zn2+ after instillation
into rat lungs
The high dose of soluble Zn2+ (277.5 μg) but not the
low dose of soluble Zn2+ (92.5 μg) caused death of the
rats because of overdose of highly toxic Zn2+ in a single
acute exposure at high dose rate. This is contrasting
with the fact that similar dose of ZnONP was associated
with 100% survival. Instillation of the low dose of solu-
ble Zn2+ caused severe eosinophilic inflammation and
mild neutrophilic inflammation at 24 h after instillation
(Figure 11). The number of eosinophils and levels of
LDH and total protein of the low dose of Zn2+ group
were significantly higher but the number of PMN was
significantly lower than those of ZnONP at 50 cm2 (Fig-
ure 11). At 4 wks after instillation, the lungs showed
very similar pathological lesions of ZnONP treatment
including goblet cell hyperplasia, fibrosis, contraction,
and atelectasis (Additional file 5).
Inflammatory profile in the BAL after ZnONP aspiration
into mice
ZnONP were inflammogenic in the lungs of C57BL/6
and BALB/c mice as evidenced by significantly increased
numbers of PMN in the BAL at 24 h. However, neither
strain showed eosinophilic inflammation at 24 h (Addi-
tional file 6). NiONP, a control particle, showed signifi-
cant PMN recruitment (data not shown). Although no
eosinophils were recruited into the BAL, the concentra-
tion of eotaxin and IL-13 in the BAL was significantly
increased compared to vehicle control following ZnONP
aspiration (Additional file 7). Although eosinophils were
not detected in the BAL fluid, TEM analysis showed
that the eosinophils were recruited in the alveolar inter-
stitium (Figure 12). NiONP, a control particle, showed
neutrophilic inflammation and neither eotaxin nor IL-13
showed significant changes compared to vehicle control
(Additional files 6 and 7).
Destabilization of lysosomes and cytotoxicity in
macrophages exposed to ZnONP in vitro
Lysosomal staining with acridine orange, showing lyso-
somal stability, waned following ZnONP treatment com-
pared to vehicle control and this was accompanied by
loss of viability (Additional file 8). In contrast, vehicle
control and TiO2NP-exposed macrophages showed high
acridine orange fluorescence intensity confirming that
these cells had intact lysosomes (Figure 13) and this was
Figure 5 Immunohistochemistry for Ki-67 in the lung tissues
treated with ZnONP at 150 cm2/rat. Each figure is composed of a
low power view (left, 25×), high power view of bronchiolar
epithelium (middle, 400×), and alveoli (right, 400×). (A) vehicle
control at 24 h; (B) ZnONP at 24 h; (C) ZnONP at 1 wk; (D) ZnONP
at 4 wks. Note that ZnONP increased the proliferating Ki-67 positive
cells (arrow) in the bronchiolar epithelium and alveolar epithelium.
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reflected in lack of cell death in the exposed macro-
phages (Additional file 8).
Discussion
In previous studies we found that zinc oxide nanoparti-
cles (ZnONP) were highly fibrogenic and caused an
eosinophil exudate into the BAL, a finding that is highly
unusual and possibly unique following particle exposure
[10]. The current paper set out to determine the likely
mechanism of the effects of ZnONP. This paper is nota-
ble by its lack of systematic inclusion of benchmark or
control particles. The reason is that we have already
published extensive findings on the ZnONP response
compared to other metal oxides and control NP [10].
The aim of the present paper was solely to investigate
the detail of the ZnONP-induced response with a view
to better understanding the mechanism whereby they
cause such severe pathological effects in rat lungs fol-
lowing a single intratracheal instillation.
In this study, ZnONP were well dispersed with serum
protein. Stability of NP depends on a balance between
attractive and repulsive forces between particles [16].
Incubation of NP with serum protein forms a protein
corona which acts as steric stabilizer preventing agglom-
eration [17]. When NP deposit in the lung, surfactant
proteins and lipids are adsorbed onto the NP forming a
Figure 6 PAS staining for goblet cells in the lung tissues treated with ZnONP at 150 cm2/rat. Each panel is composed of low power view
(left, 100×) and high power view of bronchiolar epithelium (right, 400×). (A) Vehicle control; (B) ZnONP at 24 h; (C) ZnONP at 1 wk; (D) ZnONP at 4
wks; Percentage of PAS-positive cells in the bronchus (> 1 mm in diameter) (E) and bronchiole (< 1 mm in diameter) (F). Goblet cells (arrow)
peaked at 1 wk and still present 4 wks after ZnONP instillation. Each data point represents an independent bronchus or bronchiole in the lung
tissues. Significance versus vehicle control: * p < 0.05, ** p < 0.01, # p < 0.001.
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lipoprotein corona. Therefore, intratracheal instillation
of NP dispersed with serum protein partially mimics the
interaction of NP with the lung surface environment. To
minimize xenogeneic effects, the serum protein from the
same strain animals as those used in the experiments
was used as a dispersion medium.
All NP in this study showed negative charge by zeta
potential measurement because of the negatively
charged protein corona which is the actual charge that
is encountered by cells [18]. The recognition by phago-
cytes facilitates phagocytosis which ingests NP into pha-
gosomes which are then acidified by phagosome/
lysosomes fusion. Because ZnONP showed fast dissolu-
tion in acidic solution, they are not likely to persistent
in the acid milieu of the phagolysosomes. Therefore the
effect of surface charge is likely to be less important for
high-solubility NP although insoluble positively charged
NP are more toxic than neutral or negatively charged
NP [19].
ZnONP induced pulmonary eosinophilia from 24 h to
4 wks after a single intratracheal instillation without any
prior sensitisation process. There are published studies
showing eosinophilic inflammation in animals following
various sensitisation procedures; particles such as
TiO2NP [20] and ambient particulate matter [21] have
been implicated in enhancing development of the mur-
ine model of allergic asthma. In addition, instillation or
intravenous injection of Sephadex beads (complex of
cross-linked dextran polymers; diameter: 20 - 50 μm)
also reported to cause eosinophilic inflammation in the
lung [22]. However, the eosinophilia caused by Sephadex
beads may be produced by their extremely large size
because ultrasonication of this particle produced only a
transient neutrophilic inflammation [22]. In addition,
the Sephadex beads are polymer particles which are fun-
damentally different from ZnONP used in this study.
NP-free BAL exudates collected 24 h after rats were
instilled intratracheally with ZnONP at 150 cm2 did not
produce any inflammatory reaction either at 1 wk or 4
wks. Considering that eosinophilia peaked 1 wk after
instillation and pulmonary fibrosis was mature 4 wks
after instillation, the lack of inflammation caused by
NP-free BAL exudate instillation suggest that BAL fluid
might be too diluted to produce the pathologies caused
by ZnONP instillation.
Figure 7 Picrosirius red staining of the lung tissues treated
with ZnONP at 150 cm2/rat. (A) vehicle control; (B) ZnONP at 24
h; (C) ZnONP at 1 wk; (D) ZnONP at 4 wks. Note that collagen
deposition (arrow) was increased 1 and 4 wks after instillation of
ZnONP. Bar scale: 50μm.
Figure 8 Immunohistochemistry for a-SMA, and TGF-b in the
lung tissues following treatment with ZnONP at 150 cm2/rat. (A
- D), a-SMA in the lungs. (A) vehicle control at 24 h; (B) ZnONP at
24 h; (C) ZnONP at 1 wk; (D) ZnONP at 4 wks. Note that a-SMA
positive cells (dark brown staining) were seen in smooth muscle
layer of airways and vessels of normal lung (A and B). In addition,
they were seen profusely in the fibrotic lesions (arrow) at 1 (C) and
4 wks (D) after ZnONP instillation. (E - H), TGF-b in the lungs. (E)
vehicle control at 24 h; (F) ZnONP at 24 h; (G) ZnONP at 1 wk; (H)
ZnONP at 4 wks. Note that ‘I’ denotes the area of TGF-b positive
fibrosis and the whole image of (H) was dominated by TGF-b
positivity.
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In mice, ZnONP aspiration caused eosinophilia but
eosinophils were not found in the alveoli (BAL fluid)
but were present in the alveolar interstitium. The inter-
stitial type of eosinophilia was consistent with the ele-
vated levels of eotaxin and IL-13 in the BAL.
Eosinophils in the interstitium are as likely to cause tis-
sue injury as eosinophils in the bronchoalveolar space, if
not more so [23].
We undertook a number of assays to investigate the
mechanism of the complex and severe pathological syn-
drome seen following exposure to ZnONP. In the con-
ventional rodent asthma model, recruited eosinophils
are associated with airway remodelling including peri-
bronchial fibrosis, smooth muscle hyperplasia, and
mucus secretion with the involvement of eotaxin and
IL-13 [24,25]. In the ZnONP model we found that
eotaxin and IL-13 were produced early in rats and mice
exposed to ZnONP and these are key mediators of eosi-
nophil recruitment [25,26]. IL-13 is especially involved
in the regulation of eosinophil infiltration, IgE synthesis,
goblet cell hyperplasia, mucus hypersecretion, and sub-
epithelial fibrosis in asthma [25,27]. Therefore, IL-13
provoked by ZnONP might exert an important role on
the wide spectrum of pathological effects seen here with
ZnONP exposure.
Although the main inflammatory cells induced by
ZnONP were eosinophils, PMN were also recruited during
the acute phase. PMN have been regarded as the represen-
tative acute inflammatory cells playing a role in particle
effects and their recruitment is highly correlated with the
surface area dose of low-toxicity, low-solubility particles
[28] and toxic particle such as crystalline silica [14]. The
pro-inflammatory cytokine recruiting PMN into ZnONP-
exposed lungs was most likely IL-1b which is known to
induce neutrophilic inflammation in the lung [29]. How-
ever, PMN recruitment by ZnONP was confined to the 24
h time-point whilst significant IL-1b in BAL continued to
the 1 week time-point at the highest dose.
Intratracheal instillation of ZnONP induced massive
proliferation of airway epithelial cells and goblet cell
hyperplasia. ZnONP were reported to be very cytotoxic to
BEAS-2B cells in vitro by generating reactive oxygen spe-
cies [30]. In the present study, ZnONP dramatically
increased the levels of LDH and total protein in the BAL
at the acute phase indicating cell death and increased vas-
cular permeability, respectively. Therefore, the prolifera-
tion of airway epithelial cells likely represents a
regenerative response to the cytotoxicity induced by
ZnONP. Proliferation of airway epithelial cells led to large-
scale goblet cell hyperplasia. Goblet cell hyperplasia was
most pronounced at 1 wk and had waned by 4 wks after
instillation of ZnONP. Goblet cell hyperplasia plays an
important role in protecting the airway from damage due
to inhaled particles [31]. The resulting increase in mucus
Figure 9 Transmission electron microscopy images of lungs at
4 wks after instillation of ZnONP at 150 cm2/rat. (A), vehicle
control; (B - D), ZnONP treatment group. Bar scale: B and C = 2 μm;
A and D = 5 μm. Collagen bundles (arrowhead) were found in the
perivascular region (B) and alveolar interstitium (C) where they co-
localized with eosinophils (black arrow) and PMN. Foamy
macrophages (white arrow) were localized in the alveolar spaces.
Figure 10 Pulmonary toxicity of ZnONPalt at 24 h after
instillation into lungs of rats. (A-C), BAL cell analysis at 24 h after
instillation of ZnONPalt to rats. (A) Number of total cells; (B) number
of PMN; (C) number of eosinophils. Levels of LDH (D) and total
protein (E) in the BAL fluid at 24 h after instillation of ZnONPalt to
rats. Values are mean ± S.D. n = 4 for each treatment group.
Significance versus vehicle control (VEH): * p < 0.05, ** p < 0.01, # p
< 0.001.
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flow traps inhaled particles and removes them from the
airways by muco-ciliary clearance. In addition, goblet cells
can be progenitors of ciliated cells to maintain mucus flow
[32] and hyperplasia of goblet cells is reversible on cessa-
tion of administration [31]. Hypersecretion of mucus by
goblet cell hyperplasia is also a feature of airway injury
including exposure to cigarette smoke, and sulphur diox-
ide, and in asthma where it can contribute to obstruction
of airways [33]. TGF-b is known to enhance goblet cell
hyperplasia and mucus hyper-secretion in mice through
Figure 11 Pulmonary toxicity of dissolved Zn2+ at 24 h after instillation into lungs of rats. Dissolved Zn2+ in saline was instilled at 92.5
μg/rat. (A - C), cytological analysis of BAL cells. (A), number of total cells; (B), number of PMN; (C), number of eosinophils. Levels of LDH (D) and
total protein (E) in the BAL at 24 h after instillation of ZnONP. Values are mean ± S.D. n = 4 for each treatment group. Significance versus vehicle
control (VEH): * p < 0.05, ** p < 0.01, # p < 0.001. Zn2+ (92.5 μg/rat) was compared with ZnONP at 50 cm2/rat: $ p < 0.05.
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an NF-B-dependent mechanism [24]. In this study, we
found strong immunostaining for TGF-b at all time-
points, but particularly at 1 and 4 wks after instillation
when goblet cell hyperplasia was most pronounced. Con-
sistent with the immunostaining results, total TGF-b con-
centration in the BAL was also increased at all time-
points.
Massive pulmonary fibrosis with contraction and
atelectasis was also induced by ZnONP instillation.
Following ZnONP instillation collagen fibres, deter-
mined by PSR staining, were increased from 1 wk and
were more marked at 4 wks. At 4 wks, TEM images
showed that large swathes of collagen fibres were pri-
marily located in the perivascular and alveolar intersti-
tium co-localized with eosinophils. Myofibroblasts, the
major source of extracellular matrix proteins and con-
tractile forces during fibrogenesis [34], were also seen in
the contracted and fibrotic lung lesions at 1 and 4 wks
after treatment. TGF-b also is known to cause airway
remodelling including peribronchial fibrosis and smooth
muscle hyperplasia [24].
Instillation of ZnONP increased IgE levels in the serum
but not in the BAL. Multi-walled carbon nanotubes [35],
diesel exhaust particles [36], and ultrafine carbon black
[37] have all been reported to increase serum IgE levels
by an adjuvant-like mechanism in murine asthma mod-
els. Surprisingly, compared to previous studies, the
increase in IgE levels by ZnONP were induced by just a
single instillation without any sensitization process. The
levels of IgA in the serum were decreased compared to
vehicle control. Although there was no statistical signifi-
cance, IgA levels in the BAL showed an increasing trend
at 1 wk after instillation of ZnONP. Increases in mucosal
secretory IgA were present in the BAL, and this might
explain the decrease of IgA in serum if BAL IgA was
derived from the vascular space. The increased IgA levels
in the BAL might act be anti-inflammatory in inflamed
lung [38]. TGF-b is also known to induce IgA isotype
expression by activating Smad3/4 complex translocation
into the nucleus [39].
Our data on ZnONP durability in acid and neutral
conditions suggests a mechanism for pathogenicity of
ZnONP. ZnONP were stable at neutral pH or saline but
very rapidly dissolved in the acidic artificial lysosomal
fluid (pH 4.5). Thus ZnONP in the approximately neu-
tral surfactant fluid or in the cytosol might be persistent.
However, when ZnONP are internalized into the acid
environment of the lysosome, they will be rapidly dis-
solved producing a high local concentration of Zn2+
ions. Zn2+ is one of the essential elements in cell home-
ostasis and remains in a bound form inside cells because
free Zn2+ is very reactive and cytotoxic [40]. The acute
increase in free Zn2+ levels may damage lysosomes,
allowing the contents to escape into the cytoplasm
where they may damage other organelles leading to cell
death [41,42]. We suggest therefore that Zn2+ released
from the phagolysosomes of dead or damaged cells is
the source of the Zn2+ after ZnONP uptake in the
lungs. The interaction of Zn2+ with cells generates oxi-
dative stress and finally triggers cell death signalling cas-
cades [41,43]. When ZnONP were added to activated
THP-1 cells (a differentiated macrophage cell line), lyso-
somes were destabilised by a mechanism which seems
Figure 12 Representative transmission electron microscopy
images of lungs 24 h after instillation of ZnONP at 15 cm2 to
C57BL/6 mice. (A), vehicle control; (B - D), ZnONP treatment group.
Bar scale: A = 10 μm; B = 5 μm; C and D = 2 μm. Eosinophils
(arrow) were infiltrated in the alveolar interstitium. Macrophage
(arrowhead) was severely vacuolated.
Figure 13 Lysosomal destabilization by ZnONP in THP-1 cells.
Differentiated THP-1 cells by PMA (10 ng/ml) were stained with
acridine orange for 15 min and cells were treated with NP for 24 h.
(A), vehicle control; (B) TiO2NP at 10 cm
2/ml (36.4 μg/ml); (C) ZnONP
at 10 cm2/ml (20.6 μg/ml). Acridine orange dye aggregates inside of
lysosome which showing red fluorescence. ZnONP showed less
signals compared to vehicle control or TiO2NP.
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likely to involve dissolution of ZnONP under the acid
condition of the lysosomes. Unlike ZnONP, TiO2NP
showed no dissolution in acid or neutral conditions and
when incubated with macrophages the fluorescence
intensity of lysosomes was not reduced. The loss of lyso-
somal integrity induced by ZnONP was accompanied by
cell death. A role for dissolved Zn2+ in the toxic
mechanism of ZnONP is further supported by Muller et
al. [44] who reported that ZnO nanowires were rapidly
dissolved in the acidic pH of lysosomes causing struc-
tural changes in mitochondria and cell death including
necrosis and apoptosis [44].
Instillation of dissolved Zn2+ from ZnONP treated
under acid conditions in saline, produced eosinophilia 24
h after instillation. Moreover, the toxicity of soluble Zn2+
was much greater than similar mass dose of ZnONP
based on mortality, number of eosinophils, and levels of
LDH and total protein. The higher number of eosinophils
by ZnONP than that of ZnONPalt might be due to the
smaller primary particle size and their wider distribution
inside of the lung. The chronic lung lesions caused by
Zn2+ instillation were similar to those induced by
ZnONP in terms of bronchocentric interstitial pulmonary
fibrosis, goblet cell hyperplasia, and atelectasis.
There are many inhalation/instillation studies using
zinc compounds although few papers on nanoparticles.
No papers reported eosinophilia on exposure to zinc
compounds except for our previous papers using ZnONP
[10,45] and one human case report with zinc oxide [46].
The possible reason for this discrepancy is (1) species
and strain differences, (2) location of eosinophils infiltra-
tion to the interstitium or airspaces, (3) dose, (4) polydis-
persity of particles, and (5) durability of particles. In
particular the dispersed NP size might be important as
we have shown by comparing well-dispersed and agglom-
erated NP which might specifically address the role of
ZnONP agglomerate size. We noted that large poorly-
dispersed agglomerates of ZnONP recruited much less
number and percent eosinophils (1.3%) compared to
well-dispersed ZnONP (37.7%). Based on this data we
also conclude that micron-sized particles would not
cause substantial eosinophilia in BAL following instilla-
tion. This finding is consistent with our previous study
which showed no eosinophilic inflammation with ZnON-
Palt (137 nm) using same strain of rats and instillation
technique used in here [47]. In addition, other previous
publications also showed no eosinophilic inflammation
by nano-size ZnO (50 -70 nm) or micrometer-size ZnO
(< 1000 nm) [9,48]. These previous studies instilled ZnO
without any dispersion which implies agglomeration into
much larger particles whose compartmentation in the
lung might differ from singlet NP or small agglomerates.
Therefore, the eosinophilic inflammation by ZnONP may
be elicited only by exposure to ZnONP well dispersed
and at high doses.
ZnONP-induced eosinophilia, fibrosis, and goblet cell
hyperplasia mediated by the soluble Zn2+ is to our
knowledge a novel finding in rat lungs. Interestingly,
one epidemiological study showed that the level of Zn2+
in ambient particulate matter was associated with
asthma morbidity in USA [49]. Therefore, ZnONP pose
a unique and substantial hazard to the lungs and
hygiene precautions and control of airborne exposure
should be instituted in any situation with the potential
for exposure in order to reduce the risks of the kinds of
lung pathology described here.
Conclusion
Figure 14 summarises the diverse pathological changes
(eosinophilia, airway epithelial cell injury, regenerative
goblet cell hyperplasia, bronchocentric pulmonary fibro-
sis, and atelectasis) induced by a single installation of
ZnONP. Although more studies are required, our data
suggest that a single high exposure of ZnONP produced
eosinophil influx as well as severe fibrosis and airway
epithelial injury. The main cause of these effects appears
to be the dissolution of ZnONP in the acid milieu inside
phagosomes. This study suggests that dissolution of
ZnONP to ions in the acid environment of the lyso-
somes causes lysosomal destabilisation and cell death.
The resultant widespread cell death along the path fol-
lowed by the instilled dose is likely a key factor in the
severe cell death and subsequent pathogenicity seen.
Exposure to ZnONP should be strictly regulated in
occupational/consumer setting to minimise the likeli-
hood of such severe adverse effects occurring.
Figure 14 Diagram of lung injury caused by ZnONP instillation.
ZnONP induced (1) goblet cell hyperplasia, (2) thickening of
bronchiolar smooth muscle layer, (3) eosinophilia, (4) fibrosis with
increased numbers of myofibroblasts (yellow) and collagen (thin
blue fibres), (5) perivascular edema, and (6) type II cell hyperplasia.
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Additional material
Additional file 1: Detailed materials and methods. All detailed
materials and methods were described.
Additional file 2: Immunohistochemistry for eotaxin in the lung
tissues 24 h after instillation of ZnONP at 150 cm2/rat. (A), vehicle
control; (B and C), ZnONP treatment; (D) serially sectioned H&E staining
of (C). (B) is imaged under higher magnification at 400× in (C). Note that
eotaxin was strongly positive in the bronchial epithelial cells (arrow) and
inflammatory cells (arrowhead).
Additional file 3: PAS staining for goblet cells in the lung tissues 1
wk after instillation of ZnONP at 150 cm2 per rat. Goblet cells were
found even in terminal bronchioles (arrow) but were not present in the
transitional region between bronchiolar and alveolar tissue.
Additional file 4: The effects of hydrodynamic size of ZnONP on the
eosinophilia (n = 4). This file contains the number of eosinophils in the
BAL after instillation of well-dispersed or highly agglomerated ZnONP.
Additional file 5: Representative lung lesion 4 wks after instillation
of Zn(II) at 92.5 μg per rat. (A) The lungs showed fibrosis, contraction,
atelectasis, and (B) goblet cell hyperplasia.
Additional file 6: Pulmonary toxicity of ZnONP at 24 h after
aspiration into lungs of C57BL/6 (A - C) or BALB/c (D - F) mice. (A, D),
number of total cells; (B, E), number of PMN; (C, F), number of eosinophils.
Values are mean ± S.D. n = 4 for each treatment group. Significance
versus vehicle control (VEH): * p < 0.05, ** p < 0.01, # p < 0.001.
Additional file 7: Expression of eotaxin and IL-13 in the BAL from
mice 24 h after aspiration of ZnONP or NiONP at 15 cm2 per
mouse. (A), eotaxin; (B), IL-13. Values are mean ± S.D. n = 4 for each
treatment group. Significance versus vehicle control (VEH): * p < 0.05, **
p < 0.01, # p < 0.001. NS, not significant.
Additional file 8: Cytotoxicity of THP-1 cells after exposure to NP
for 24 h, measured as percentage compared to complete lysis
(Triton X-100). THP-1 cells were differentiated by treatment with PMA
(10 ng/ml) for 48 h and LDH levels were measured 24 h after NP
treatment. Values are mean ± S.D. n = 4 for each treatment group.
Significance versus vehicle control (VEH): # p < 0.001.
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